{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diarrhoea-antibiotic-associated/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"86cd74d6-6f35-5de4-9031-55397958409b","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 88620f7c-64cd-4724-982c-9557521e3558 --><h2>Update</h2><!-- end field 88620f7c-64cd-4724-982c-9557521e3558 -->","summary":null,"htmlStringContent":"<!-- begin item 75d46f43-9432-4244-8db3-9d707c37b07f --><!-- end item 75d46f43-9432-4244-8db3-9d707c37b07f -->","topic":{"id":"e3d5d597-cb8d-5009-95be-96d5f61f622c","topicId":"60505e59-3d44-4100-ba77-670b2dda81a3","topicName":"Diarrhoea - antibiotic associated","slug":"diarrhoea-antibiotic-associated","lastRevised":"Last revised in November 2020","chapters":[{"id":"ff00d31e-fff0-5539-893c-63eaae28aa91","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d4f02cb1-a605-5763-85b8-7e30efe0b52d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b4be21a4-fea2-52ee-99b9-6ad9b7f42b37","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"14b5fd2c-0a9a-58b3-af3b-54e8f6c587a3","slug":"changes","fullItemName":"Changes"},{"id":"86cd74d6-6f35-5de4-9031-55397958409b","slug":"update","fullItemName":"Update"}]},{"id":"d9b8d789-d6e6-5a0f-80ef-2853843c67b6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"93a9787b-a3ca-5bd2-9dd1-e7bd5ebd7e61","slug":"goals","fullItemName":"Goals"},{"id":"712c6134-ba14-5e2a-987b-8d3c06033ee0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"04b62294-302f-5852-90f5-60c1f9593a96","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"98b4954c-4b96-5b7a-9888-99cfd0b2ce3d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7f04cf05-c2de-5fb3-9f58-b7e32b7a8604","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d849aa0f-051e-5e61-8d05-6da99fdc60e0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"146be3ba-ef2c-5d7c-a6be-75d743b6cbdb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3deeffef-b60e-557b-a9ce-2ca055de0653","slug":"definition","fullItemName":"Definition"},{"id":"788d8348-35a0-5147-b765-a90a068257b9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7804f825-6a78-5c22-89f7-9ecb4f2ac588","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4d2b177e-1c5d-5783-b256-b0b7173e4660","slug":"complications","fullItemName":"Complications"},{"id":"0d3b3c20-ff70-5653-9cb1-750667c15098","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"db6311c9-b63f-5037-89f3-fe2ed41761c7","fullItemName":"Management","slug":"management","subChapters":[{"id":"1ddecd55-2bf4-53db-8594-8c1489126404","slug":"diarrhoea-antibiotic-associated","fullItemName":"Scenario: Diarrhoea - antibiotic associated"}]},{"id":"e0650ec6-ca9b-5cf0-9761-2ffe00571666","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4f209e3e-56a5-5f47-859e-8b6f0b9b9fe9","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"1a19af07-ea9e-59ac-8ce6-508d4d01e536","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ecd4dd69-cf4c-507f-9659-b23f2a5b3272","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b0079d2b-b8c1-59e3-a1c1-f6f2c83a07c5","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"919502d7-1740-58a4-8ea5-2feeb47d6e28","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d1844305-0beb-50de-a2de-fbea6a58b880","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"766c971f-c448-56d3-a9d4-2ffded846f90","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7d18a1e0-eeb3-5b2f-bd26-e9f231d83c40","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"99309640-cab2-57c4-8bd0-2c05065abd69","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b4be21a4-fea2-52ee-99b9-6ad9b7f42b37","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"ef4227cf-1d2d-52d1-8cac-1b8169e4af77","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 5fef797b-95f0-448b-8d2d-da9020c87460 --><h3>New evidence</h3><!-- end field 5fef797b-95f0-448b-8d2d-da9020c87460 -->","summary":null,"htmlStringContent":"<!-- begin item 9fecce13-3bef-480e-ac4b-f3394d33c491 --><!-- begin field ff48d552-df4b-4149-a18a-9d82a9a9400a --><h3>Evidence-based guidelines</h3><!-- end field ff48d552-df4b-4149-a18a-9d82a9a9400a --><!-- begin field 4b823354-208f-40be-bb92-be0176cadb59 --><p>NHS Improvement (2019) <em>Clostridium difficile infection objectives. </em>NHS Improvement. <a href=\"https://improvement.nhs.uk/\" data-hyperlink-id=\"43121d23-fbcf-42bd-b10f-aa6f00cd4dc8\">www.improvement.nhs.uk</a> [<a href=\"https://improvement.nhs.uk/resources/clostridium-difficile-infection-objectives/\" data-hyperlink-id=\"a665bcf8-e122-45b1-8efa-aa6f00cd4e9e\">Free Full-text</a>]</p><!-- end field 4b823354-208f-40be-bb92-be0176cadb59 --><!-- begin field 2655d0da-b917-49bb-8066-1847aa6714f1 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 2655d0da-b917-49bb-8066-1847aa6714f1 --><!-- begin field 8362951a-0f1b-47b9-9095-e0c57368f5b1 --><p>No new HTAs since 1 January 2019.</p><!-- end field 8362951a-0f1b-47b9-9095-e0c57368f5b1 --><!-- begin field 4a5a341a-6f1e-4fe8-b102-8488ef5550df --><h3>Economic appraisals</h3><!-- end field 4a5a341a-6f1e-4fe8-b102-8488ef5550df --><!-- begin field 9de654da-8913-452c-b04f-22e654e63258 --><p>No new economic appraisals relevant to England since 1 January 2019.</p><!-- end field 9de654da-8913-452c-b04f-22e654e63258 --><!-- begin field d99c492c-81b4-4f4f-b82e-9025cecb1a54 --><h3>Systematic reviews and meta-analyses</h3><!-- end field d99c492c-81b4-4f4f-b82e-9025cecb1a54 --><!-- begin field 211afa69-7e4b-4478-a97a-6ae8edc514dc --><ul><li>Drugs and Therapeutics Bulletin (2019) Comparison of antibiotics for <em>Clostridium difficile</em> infection. British Medical Journal. <a href=\"https://dtb.bmj.com/\" data-hyperlink-id=\"12912502-a2d5-4ea2-bae8-aa3f00d3705b\">www.dtb.bmj.com</a> [<a href=\"https://dtb.bmj.com/content/57/5/71\" data-hyperlink-id=\"f6d3e7b1-275d-45aa-9b50-aa3f00d37075\">Free Full-text</a>]</li></ul><!-- end field 211afa69-7e4b-4478-a97a-6ae8edc514dc --><!-- begin field a36c3ad2-28c1-46a2-ad67-7f4338b11fd1 --><h3>Primary evidence</h3><!-- end field a36c3ad2-28c1-46a2-ad67-7f4338b11fd1 --><!-- begin field 12bf33b6-dc23-40a3-b65d-11f11b2c0b85 --><p>No new randomized controlled trials published in the major journals since 1 January 2019.</p><!-- end field 12bf33b6-dc23-40a3-b65d-11f11b2c0b85 --><!-- end item 9fecce13-3bef-480e-ac4b-f3394d33c491 -->","subChapters":[]},{"id":"0b287b11-ef83-57bb-94aa-0eb37f176c53","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 7d3c39e1-98a0-42af-8a7c-fd79c8bd51f5 --><h3>New policies</h3><!-- end field 7d3c39e1-98a0-42af-8a7c-fd79c8bd51f5 -->","summary":null,"htmlStringContent":"<!-- begin item 9b5e8913-8ed4-4cdb-87d0-e99f2d7edce6 --><!-- begin field 266d2bd3-4127-4115-aa0d-2790e1d651b9 --><p>No new policies since 1 January 2019.</p><!-- end field 266d2bd3-4127-4115-aa0d-2790e1d651b9 --><!-- end item 9b5e8913-8ed4-4cdb-87d0-e99f2d7edce6 -->","subChapters":[]},{"id":"4e1c621a-b0ad-57a1-8a3c-492839221d0a","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field ebfdaf2a-c888-46a7-953b-420bd01befaf --><h3>New safety alerts</h3><!-- end field ebfdaf2a-c888-46a7-953b-420bd01befaf -->","summary":null,"htmlStringContent":"<!-- begin item c69eb2b1-6f6f-4cf3-a9bd-54ce03fe8299 --><!-- begin field 5954a653-e7cd-48a5-be9c-907c7da6fc53 --><p>No new safety alerts since 1 January 2019.</p><!-- end field 5954a653-e7cd-48a5-be9c-907c7da6fc53 --><!-- end item c69eb2b1-6f6f-4cf3-a9bd-54ce03fe8299 -->","subChapters":[]},{"id":"2c0f092c-5db6-58c8-bc59-99f0b3e19aa2","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 49a975e2-c2bc-4db7-8fe5-e5c26a86e9bb --><h3>Changes in product availability</h3><!-- end field 49a975e2-c2bc-4db7-8fe5-e5c26a86e9bb -->","summary":null,"htmlStringContent":"<!-- begin item a8bd6f59-3b4a-4b17-8bb5-996a111b406c --><!-- begin field 6b67489a-889f-47ff-9a86-ac9cb3964112 --><ul><li>European Committee for Medicinal Products for Human Use issues (CHMP) positive opinion on license extension of fidaxomicin (Dificlir)CHMP recommended an extension to the existing indication; from treatment of Clostridioides difficile infections in adults, to both adult and paediatric patients with a body weight of at least 12.5 kg. For more information, see <a href=\"https://www.ema.europa.eu/en/medicines/human/summaries-opinion/dificlir\" data-hyperlink-id=\"82781321-aa36-49a5-9c13-ab5000e50bb0\">here</a>.</li></ul><!-- end field 6b67489a-889f-47ff-9a86-ac9cb3964112 --><!-- end item a8bd6f59-3b4a-4b17-8bb5-996a111b406c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}